What psychedelic businesses can and cannot say in marketing

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

For licensed psilocybin service centers, natural medicine healing centers, facilitators, and other psychedelic businesses who want to understand what marketing and advertising claims are legally permissible — and what claims create regulatory, legal, and platform-level risk.

The short answer

Marketing a psychedelic business sits at the intersection of three overlapping legal frameworks: OPS and DORA rules that prohibit specific types of claims about psilocybin services; Federal Trade Commission rules that prohibit deceptive advertising including unsubstantiated health claims; and platform-level policies at major digital advertising and social media companies that restrict or prohibit psychedelic content regardless of legality under state law. A service center or facilitator who markets their business without understanding all three frameworks is exposed to OPS or DORA discipline, FTC scrutiny, and the practical problem of having their accounts and advertising suspended. The governing principle is simple to state but requires careful application: describe what you offer, not what it will do for clients.

OPS rules on marketing claims

OAR 333-333-6040 prohibits licensed service centers and facilitators from making dishonest, misleading, or deceptive statements about psilocybin services. Several specific categories of prohibited statements flow from this rule and from the broader ORS 475A framework.

Health and medical claims are prohibited. A service center cannot represent psilocybin services as treating, curing, managing, or having demonstrated efficacy for any health condition — depression, PTSD, anxiety, addiction, or any other condition. OPS rules make clear that psilocybin services are wellness services, not medical or clinical treatment. The informed consent document every client signs states this explicitly. A service center whose website, social media, or marketing materials claim that psilocybin services treat depression has violated OAR 333-333-6040 regardless of what the clinical trial evidence suggests.

Describing services as therapy is prohibited in Oregon. OAR 333-333-6040 specifically prohibits using the word “therapy” or “therapeutic” to describe psilocybin services provided at a licensed service center, because those terms imply a clinical treatment relationship that OPS’s facilitation model does not constitute. The prohibition applies to the service center’s own marketing — it does not prevent clients or media from using those words.

Misrepresenting facilitator credentials or experience is prohibited. A facilitator who has completed the 160-hour OPS training program cannot represent themselves as having clinical training they do not possess, or as having specialized experience with specific populations if they do not.

Guaranteeing outcomes is prohibited. Psilocybin experiences are highly variable. Any marketing claim that guarantees a specific experience, emotional outcome, or personal transformation misleads prospective clients and violates OAR 333-333-6040’s prohibition on deceptive statements.

What service centers and facilitators can say

Marketing psilocybin services is not prohibited — it is constrained. The space of permissible marketing is defined by what is factually accurate, not misleading, and not expressly prohibited under OPS rules or applicable advertising law.

A service center can describe what the OPS program is and how it works — the three session types, the preparation and integration framework, the non-directive approach, what a session at this specific center involves in terms of environment, duration, and practitioner background.

A service center can describe the facilitator’s background and training — OPS certification, prior professional experience, training program completed, areas of personal interest and focus — provided those descriptions are accurate.

A service center can reference the existing research on psilocybin, provided the reference is accurate and qualified. Saying “research suggests psilocybin may have potential for treatment-resistant depression” is factually defensible. Saying “psilocybin cures depression” is not.

A service center can share client testimonials, subject to the FTC rules discussed in article 100 and provided those testimonials do not make prohibited health claims.

A service center can describe its approach to the facilitation relationship — the values, philosophy, and environment the center brings to sessions — without making claims about outcomes.

The therapy prohibition in depth

Oregon’s prohibition on using the word “therapy” in marketing psilocybin services deserves specific attention because it runs counter to how the public and most media describe what happens in a psilocybin session. The prohibition applies specifically to OPS-licensed services — a service center cannot call what it offers “psilocybin-assisted therapy” or “psychedelic therapy” or “psilocybin therapy” in its marketing.

The reason is structural: Oregon’s facilitation model is not a clinical therapy model. Facilitators are not licensed therapists in their capacity as facilitators (even if they hold a separate therapy license). The session is not a clinical treatment. Using the word “therapy” to describe it misrepresents the nature of what OPS licenses and creates potential for clients to confuse a wellness service with clinical care.

This prohibition creates friction with the broader public discourse about psychedelics, in which the phrase “psychedelic-assisted therapy” is ubiquitous. A service center can reference the research literature’s use of that phrase without endorsing it as a descriptor for their own services — “research on psychedelic-assisted therapy suggests…” is different from “our psilocybin-assisted therapy sessions offer…”

The FTC framework

The Federal Trade Commission Act (15 U.S.C. § 45) prohibits unfair or deceptive acts or practices in commerce. The FTC’s advertising rules apply to psychedelic businesses to the same extent they apply to any business advertising goods or services.

The most relevant FTC principles for psychedelic marketing: advertising claims must be truthful and not misleading; health-related claims must be substantiated by competent and reliable scientific evidence; testimonials and endorsements must reflect the honest opinions of the person giving them; and material connections between an endorser and the business must be disclosed. These principles are addressed in more detail in articles 100 and 105.

Platform-level advertising constraints

Major digital advertising platforms — Google Ads, Meta (Facebook and Instagram), YouTube — prohibit advertising for controlled substances regardless of state law legality. Psilocybin’s Schedule I status means these platforms’ standard policies prohibit paid advertising for psilocybin services. A service center that attempts to run paid digital advertising through these platforms will find its ads disapproved and its account subject to suspension.

Some platforms have created limited exceptions or policy pathways for cannabis businesses in states where cannabis is legal — those pathways generally do not extend to psilocybin. Emerging digital advertising platforms that specialize in cannabis and psychedelic content have developed as an alternative, though their reach is smaller than the major platforms.

Organic content — non-paid social media posts, website content, blog posts, newsletters — is not subject to platform advertising policies in the same way as paid advertising. A service center can maintain a presence on Instagram, Facebook, or YouTube through organic content, though platform community standards around health claims and drug-related content apply and accounts promoting psychedelic content have been removed from major platforms without warning.

Oregon Unlawful Trade Practices Act

The Oregon Unlawful Trade Practices Act (ORS 646.605–646.656) applies to the sale of services and prohibits false representations about the nature, characteristics, or quality of services. A service center that makes false or misleading marketing claims about its psilocybin services — overstating facilitator credentials, making unsubstantiated health claims, misrepresenting what the service includes — faces UTPA exposure in addition to OPS discipline. The UTPA provides for minimum statutory damages of $200 per violation even without proof of actual loss, plus attorney fees to prevailing plaintiffs, making UTPA claims economically viable for clients who relied on misleading marketing.

Practical marketing guidance

A useful test for any proposed marketing claim: would a reasonable prospective client reading this claim receive an accurate understanding of what they are purchasing? If the claim implies that psilocybin services will treat their depression, that the facilitator has clinical training they do not have, or that the experience is guaranteed to produce a specific outcome, the claim fails the test.

Effective marketing for a psilocybin service center focuses on the tangible and verifiable: the physical environment, the facilitator’s background and approach, the program structure, the cost and what it includes, the service center’s values, and accurate references to existing research. It does not reach for outcomes it cannot promise or clinical characterizations the regulatory framework prohibits.

When public information may be enough

OAR 333-333-6040 is publicly available through the Oregon Secretary of State’s administrative rules database. The FTC’s advertising guidelines, including its guidelines for health claims and endorsements, are at ftc.gov. Oregon’s UTPA (ORS 646.605–646.656) is available through the Oregon Legislative Assembly. Platform advertising policies are available on each platform’s business advertising policy pages.

When you should speak with a lawyer

A service center developing its website, social media presence, and marketing materials for the first time should have those materials reviewed by an attorney familiar with both OPS marketing rules and FTC advertising standards before publishing. A service center that has received a complaint from OPS about its marketing claims, or a demand letter from a client alleging misleading advertising, should retain counsel immediately before responding.

You might also want to read

This article is for general informational purposes only and does not constitute legal advice. Marketing regulations, platform policies, and FTC guidance change frequently. For advice specific to your marketing materials, consult a licensed attorney with experience in psychedelic business and advertising law.